Lucid Diagnostics (NASDAQ:LUCD) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

by · The Cerbat Gem

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) had its price target increased by equities research analysts at Ascendiant Capital Markets from $8.00 to $8.25 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other equities analysts have also weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a report on Thursday, November 13th. BTIG Research increased their target price on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the stock a “buy” rating in a research note on Friday, September 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Lucid Diagnostics in a research note on Monday. Finally, Wall Street Zen downgraded Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $3.94.

Read Our Latest Stock Report on LUCD

Lucid Diagnostics Stock Performance

Shares of LUCD opened at $1.10 on Wednesday. The business’s 50-day moving average is $1.12 and its two-hundred day moving average is $1.14. The company has a market capitalization of $151.45 million, a P/E ratio of -1.06 and a beta of 1.22. Lucid Diagnostics has a fifty-two week low of $0.75 and a fifty-two week high of $1.80.

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The firm had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $1.35 million. Analysts forecast that Lucid Diagnostics will post -0.84 EPS for the current year.

Hedge Funds Weigh In On Lucid Diagnostics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. purchased a new position in Lucid Diagnostics in the first quarter worth approximately $2,813,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Lucid Diagnostics during the first quarter worth approximately $37,000. Goldman Sachs Group Inc. boosted its holdings in Lucid Diagnostics by 35.7% in the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after purchasing an additional 22,727 shares in the last quarter. Ghisallo Capital Management LLC purchased a new position in Lucid Diagnostics in the first quarter valued at approximately $629,000. Finally, Parallel Advisors LLC acquired a new stake in Lucid Diagnostics during the second quarter worth approximately $46,000. Institutional investors and hedge funds own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

(Get Free Report)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

Read More